Ausgabe 5/2005
Inhalt (12 Artikel)
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer
Christina H. Yeon, Mark D. Pegram
Novel therapy in multiple myeloma
Agustin Avilés, Natividad Neri, M. Jesús Nambo, Sergio Cleto, Claudia Castañeda, Martha González, Alejandra Talavera, Judith Huerta-Guzmán
Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists
Doris M. Benbrook, Scott A. Kamelle, Suresh B. Guruswamy, Stan A. Lightfoot, Teresa L. Rutledge, Natalie S. Gould, Bethany N. Hannafon, S. Terence Dunn, K. Darrell Berlin
Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer
J. H. Beumer, J. M. Rademaker-Lakhai, H. Rosing, L. Lopez-Lazaro, J. H. Beijnen, J. H. M. Schellens
An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin
H. Hirte, D. Stewart, R. Goel, E. Chouinard, S. Huan, S. Stafford, B. Waterfield, S. Matthews, C. Lathia, B. Schwartz, V. Agarwal, R. Humphrey, and L. Seymour
A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130
Karen A. Gelmon, Karl Belanger, Denis Soulieres, Carolyn Britten, Stephen Chia, Danielle Charpentier, Kim Chi, Jean Powers, Wendy Walsh, Lesley Seymour
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies
Eric X. Chen, Gerald Batist, Lillian L. Siu, Naeema Bangash, Martha Maclean, Lynn McIntosh, Wilson H. Miller Jr, Amit M. Oza, Chetan Lathia, Oana Petrenciuc, Lesley Seymour
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer
Ranjana Advani, Bert L. Lum, George A. Fisher, Joanne Halsey, Richard S. Geary, Jon T. Holmlund, T. Jesse Kwoh, F. Andrew Dorr, Branimir I. Sikic
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer
Jaffer A. Ajani, Chris Takimoto, Carlos R. Becerra, Alejandro Silva, Luis Baez, Allen Cohn, Pierre Major, Makio Kamida, Kevie Feit, Robert De Jager
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study
John S. Macdonald, Sheryl McCoy, Robert P. Whitehead, Syma Iqbal, James L. Wade III, Jeffrey K. Giguere, James L. Abbruzzese
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers
Hedy L. Kindler, Peter K. Tothy, Robert Wolff, Richard A. McCormack, James L. Abbruzzese, Sridhar Mani, Kurombi T. Wade-Oliver, Everett E. Vokes
Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial
Evanthia Galanis, Jan C. Buckner, Matthew J. Maurer, Joel M. Reid, Mary J. Kuffel, Matthew M. Ames, Bernd W. Scheithauer, Julie E. Hammack, George Pipoly, Steven A. Kuross